Revelation Biosciences, Inc. (REVB)
NASDAQ: REVB · Real-Time Price · USD
0.413
+0.013 (3.20%)
At close: Jan 21, 2025, 4:00 PM
0.422
+0.009 (2.18%)
After-hours: Jan 21, 2025, 7:55 PM EST
Company Description
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics.
It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.
The company was founded in 2020 and is based in San Diego, California.
Revelation Biosciences, Inc.
| Country | United States |
| Founded | 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | James Rolke |
Contact Details
Address: 4660 La Jolla Village Drive, Suite 100 San Diego, California 92122 United States | |
| Phone | 650 800 3717 |
| Website | revbiosciences.com |
Stock Details
| Ticker Symbol | REVB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001810560 |
| CUSIP Number | 76135L101 |
| ISIN Number | US76135L5075 |
| Employer ID | 84-3898466 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| James M. Rolke | Chief Executive Officer and Director |
| Chester Stanley Zygmont III | Chief Financial Officer and Corporate Secretary |
| Sandra Vedrick | Vice President of Human Resources and Investor Relations |
| Carol Odle | Senior Director of Clinical Projects |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 21, 2025 | 8-K | Current Report |
| Jan 13, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jan 7, 2025 | 8-K | Current Report |
| Jan 2, 2025 | SCHEDULE 13G/A | Filing |
| Dec 20, 2024 | EFFECT | Notice of Effectiveness |
| Dec 20, 2024 | 424B3 | Prospectus |
| Dec 19, 2024 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Dec 16, 2024 | DEF 14A | Other definitive proxy statements |
| Dec 12, 2024 | 8-K | Current Report |
| Dec 12, 2024 | S-3 | Registration statement under Securities Act of 1933 |